Access here alternative investment news about Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive Cgrp-targeting Monoclonal Antibodies
LPNEWS

Biohaven Announces Expanded Safety And Preliminary Preventive Efficacy Data From Ongoing Long-term Safety Study, And Presents Case Reports Of Using Rimegepant To Successfully Treat Breakthrough Migraine Attacks In Patients Taking Preventive Cgrp-targeting Monoclonal Antibodies

by prnewswire.com posted 1year ago 170 views
NEW HAVEN, Conn., May 7, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced additional safety and preliminary efficacy results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor...

In this article